There has been a recent shortage of a number of menopausal hormone therapy (MHT) preparations and some of these have now been or soon will be resolved:

Oral MHT

Duavive – supply due to be resolved by end January 2022 

Transdermal

Estradot 100 – supply due to be resolved by the end of March

Estradot 75 – supply due to be resolved by the end of April

Estradot 50 – supply due to be resolved by the end of March

Estradot 37.5 – supply due to be resolved by the end of March

Estradot 25 – supply due to be resolved by the end of April

Estalis Conti 50/140 - supply due to be resolved by early April

Estalis Conti 50/250 - supply due to be resolved by early April

Estalis Sequi 50/140 – supply due to be resolved by early May

Estalis Sequi 50/250 – supply due to be resolved by early May

Estraderm MX 50 – supply due to be resolved by end of April

Estraderm MX 100 - supply due to be resolved by end of April

Please note that dates for supply have been sourced from either the pharmaceutical supplier or the TGA website and may change at any time.

AMS would like to congratulate AMS and IMS Past-President Professor Susan Davis on being awarded an Officer (AO) in the General Division for distinguished service of a high degree to Australia or humanity at large.

Sue was awarded the Australia Day Honour for distinguished service to medicine, to women's health as a clinical endocrinologist and researcher, and to medical education.

Many of you would know how tirelessly Sue has worked in women’s health and particularly in menopause education and research.

Congratulation Sue on your award, which is most deserving.